December 15th, 2010

Today’s Organizational Announcements

Earlier today, we issued a press release announcing that Alex Gorsky, currently Worldwide Chairman, Medical Devices & Diagnostics and Sheri McCoy, currently Worldwide Chairman, Pharmaceuticals, have been appointed Vice Chairmen of the Executive Committee and join William C. Weldon, Chairman of the Board and Chief Executive Officer, in an expanded Office of the Chairman. Both appointments are effective January 3, 2011. In the communication distributed globally to all Johnson & Johnson employees, Bill summed up these organizational changes in the following way:

As the Johnson & Johnson Family of Companies continues to grow and we look toward opportunities and challenges of the future, it is important for us to regularly assess our organizations to ensure that they remain focused strategically, resourced properly and structured appropriately.

Today I am announcing organizational realignments within our leadership team that are being taken to ensure that we continue to be well positioned for sustainable growth into the future. Our organizational changes are an appropriate step in furthering our long-term succession plans within Johnson & Johnson, assuring talented, experienced leaders at all levels of the organization. The changes remain consistent with our philosophy of decentralization and are designed to improve Johnson & Johnson’s capacity to grow and to provide a platform for effective and efficient operations.

2 Responses to “Today’s Organizational Announcements”

  1. Keith F. says

    I remain skeptical about the ability of JNJ’s executives to create value for shareholders. The terrible stewardship of this company over the past 5+ years has been worrisome for both myself and my family, each of whom are large shareholders in the company. I find myself becoming more distrustful of the leadership at JNJ, particularly in light of the recent recalls and issues at JNJ’s production plants. Under YOUR leadership, the Johnson & Johnson franchise/ brand (that took decades to build up), has been seriously damaged.

    My hope is that JNJ’s executives refocus its efforts in creating value for its shareholders and customers. But, in light of recent events surrounding lack of institutional control with its production of various OTC medicines, I find it hard to believe that the necessary changes will be instituted.

    JNJ’s management team has become lazy and this is reflective in the issues noted above. Changes need to be made both to the management team and to its culture because, in my opinion, it is eroding confidence that this company will remain a leader in its respective field(s)—on an industry, company and division-wide basis.

    Thank you for your time.

  2. Howard says

    I totally agree and have couldn’t said it better.

    It takes a lifetime to build up the level of trust and just a short time to tear it down.

    Decisions were made that were just plain wrong. In my opinion, they were at odds with writings and philosophy of the ‘General’, whose wise guidance built the company into the gold standard it was.

    I can still remember our team carefully checking the printing on the outside corrugated shipper just because that was expected and required and most of all had the company name on it. It had to look pristine and was the representative of the company and the corporation.

Leave a Reply

All comments will be reviewed before posting. Since this blog is about Johnson & Johnson, comments that don’t directly relate to the Company or to topics covered on this blog won’t be posted. Please see our comments policy for details.